• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

皮下给予小鼠时,鼠源单克隆抗体亚微米颗粒比可溶性低聚体或微米颗粒具有更强的免疫原性。

Submicron Size Particles of a Murine Monoclonal Antibody Are More Immunogenic Than Soluble Oligomers or Micron Size Particles Upon Subcutaneous Administration in Mice.

机构信息

Division of BioTherapeutics, Leiden University, Leiden, The Netherlands.

Analytical Sciences, MedImmune LLC, Gaithersburg, Maryland 20878.

出版信息

J Pharm Sci. 2018 Nov;107(11):2847-2859. doi: 10.1016/j.xphs.2018.06.029. Epub 2018 Jul 10.

DOI:10.1016/j.xphs.2018.06.029
PMID:30003898
Abstract

Protein aggregates are one of the several risk factors for undesired immunogenicity of biopharmaceuticals. However, it remains unclear which features determine whether aggregates will trigger an unwanted immune response. The aim of this study was to determine the effect of aggregates' size on their relative immunogenicity. A monoclonal murine IgG1 was stressed by exposure to low pH and elevated temperature followed by stirring to obtain aggregates widely differing in size. Aggregate fractions enriched in soluble oligomers, submicron size particles and micron size particles were isolated via centrifugation or size-exclusion chromatography and characterized physicochemically. The secondary and tertiary structures of aggregates were altered in a similar way for all the fractions, while no substantial chemical degradation was observed. Development of anti-drug antibodies was measured after subcutaneous administration of each enriched fraction to BALB/c mice. Among all tested fractions, the most immunogenic was the one highly enriched in submicron size particles (∼100-1000 nm). Fractions composed of micron size (>1-100 μm) particles or soluble oligomers (<100 nm) were not immunogenic under the dosing regimen studied in this work. These results show that aggregate size is an important factor for protein immunogenicity.

摘要

蛋白质聚集体是生物制药产生非预期免疫原性的几个风险因素之一。然而,目前尚不清楚哪些特征决定了聚集体是否会引发不受欢迎的免疫反应。本研究旨在确定聚集体大小对其相对免疫原性的影响。通过暴露于低 pH 值和升高的温度并随后搅拌,使单克隆鼠 IgG1 产生大小差异很大的聚集体。通过离心或大小排阻层析从聚集体中分离出富含可溶性寡聚物、亚微米大小颗粒和微米大小颗粒的级分,并对其进行物理化学特性表征。所有级分的聚集体的二级和三级结构都以相似的方式发生改变,而没有观察到实质性的化学降解。在 BALB/c 小鼠中皮下给予每种富集级分后,测量抗药物抗体的产生。在所研究的给药方案中,在所测试的所有级分中,最具免疫原性的是高度富含亚微米大小颗粒(约 100-1000nm)的级分。由微米大小(>1-100μm)颗粒或可溶性寡聚物(<100nm)组成的级分在本工作研究的给药方案中没有免疫原性。这些结果表明,聚集体大小是蛋白质免疫原性的一个重要因素。

相似文献

1
Submicron Size Particles of a Murine Monoclonal Antibody Are More Immunogenic Than Soluble Oligomers or Micron Size Particles Upon Subcutaneous Administration in Mice.皮下给予小鼠时,鼠源单克隆抗体亚微米颗粒比可溶性低聚体或微米颗粒具有更强的免疫原性。
J Pharm Sci. 2018 Nov;107(11):2847-2859. doi: 10.1016/j.xphs.2018.06.029. Epub 2018 Jul 10.
2
Fate of Multimeric Oligomers, Submicron, and Micron Size Aggregates of Monoclonal Antibodies Upon Subcutaneous Injection in Mice.单克隆抗体多聚体寡聚体、亚微米和微米级聚集体在小鼠皮下注射后的命运
J Pharm Sci. 2016 May;105(5):1693-1704. doi: 10.1016/j.xphs.2016.02.034. Epub 2016 Apr 1.
3
Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice.小鼠单克隆抗体不同类型聚集体在小鼠体内的免疫原性研究。
Pharm Res. 2015 Feb;32(2):430-44. doi: 10.1007/s11095-014-1472-6. Epub 2014 Aug 15.
4
Monoclonal Antibody Dimers Induced by Low pH, Heat, or Light Exposure Are Not Immunogenic Upon Subcutaneous Administration in a Mouse Model.低 pH 值、热或光照诱导的单克隆抗体二聚体在小鼠模型中皮下给予时不具有免疫原性。
J Pharm Sci. 2020 Jan;109(1):730-738. doi: 10.1016/j.xphs.2019.04.021. Epub 2019 Apr 25.
5
Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.通过荧光激活细胞分选分离成大小富集群体的高度聚集抗体的物理表征和体外生物学影响。
J Pharm Sci. 2015 May;104(5):1575-91. doi: 10.1002/jps.24379. Epub 2015 Mar 5.
6
The immunogenicity of antibody aggregates in a novel transgenic mouse model.新型转基因小鼠模型中抗体聚集体的免疫原性
Pharm Res. 2015 Jul;32(7):2344-59. doi: 10.1007/s11095-015-1627-0. Epub 2015 Jan 29.
7
The Effect of Small Oligomeric Protein Aggregates on the Immunogenicity of Intravenous and Subcutaneous Administered Antibodies.小寡聚体蛋白聚集体对静脉注射和皮下注射抗体免疫原性的影响
J Pharm Sci. 2015 Nov;104(11):3691-3702. doi: 10.1002/jps.24592. Epub 2015 Jul 30.
8
Antibody responses in mice to particles formed from adsorption of a murine monoclonal antibody onto glass microparticles.小鼠对通过将鼠单克隆抗体吸附到玻璃微粒上形成的颗粒的抗体反应。
J Pharm Sci. 2014 Jan;103(1):78-89. doi: 10.1002/jps.23772. Epub 2013 Nov 13.
9
Extensive Chemical Modifications in the Primary Protein Structure of IgG1 Subvisible Particles Are Necessary for Breaking Immune Tolerance.IgG1亚可见颗粒一级蛋白质结构中的广泛化学修饰对于打破免疫耐受是必要的。
Mol Pharm. 2017 Apr 3;14(4):1292-1299. doi: 10.1021/acs.molpharmaceut.6b00816. Epub 2017 Mar 7.
10
Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.IgG4 单克隆抗体稀释至不同静脉输注袋后的相容性、物理稳定性和特性。
J Pharm Sci. 2012 Oct;101(10):3636-50. doi: 10.1002/jps.23224. Epub 2012 Jun 25.

引用本文的文献

1
Nonintuitive Immunogenicity and Plasticity of Alpha-Synuclein Conformers: A Paradigm for Smart Delivery of Neuro-Immunotherapeutics.α-突触核蛋白构象体的非直观免疫原性和可塑性:神经免疫疗法智能递送的范例
Pharmaceutics. 2024 Apr 30;16(5):609. doi: 10.3390/pharmaceutics16050609.
2
A High Threshold of Biotherapeutic Aggregate Numbers is Needed to Induce an Immunogenic Response In Vitro, In Vivo, and in the Clinic.高生物治疗聚集物数量阈值是诱导体外、体内和临床免疫原性反应所必需的。
Pharm Res. 2024 Apr;41(4):651-672. doi: 10.1007/s11095-024-03678-2. Epub 2024 Mar 22.
3
Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry.
制药行业中基于蛋白质的治疗药物的稳定性挑战与聚集
RSC Adv. 2023 Dec 11;13(51):35947-35963. doi: 10.1039/d3ra06476j. eCollection 2023 Dec 8.
4
Optimizing a therapeutic humanized follicle-stimulating hormone-blocking antibody formulation by protein thermal shift assay.通过蛋白热迁移分析优化治疗性人源化卵泡刺激素阻断抗体制剂。
Ann N Y Acad Sci. 2023 Mar;1521(1):67-78. doi: 10.1111/nyas.14952. Epub 2023 Jan 11.
5
Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors.K-Ras(G12D)-抑制肽 KS-58 的纳米制剂抑制结直肠和胰腺癌细胞来源的肿瘤。
Sci Rep. 2023 Jan 10;13(1):518. doi: 10.1038/s41598-023-27825-8.
6
Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses.纳米疫苗:在增强抗肿瘤免疫反应方面的优点和多种作用。
Hum Vaccin Immunother. 2022 Nov 30;18(6):2119020. doi: 10.1080/21645515.2022.2119020. Epub 2022 Sep 28.
7
Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates.自发性产生的治疗性单克隆抗体聚集体的免疫原性风险评估。
Front Immunol. 2022 Jul 27;13:915412. doi: 10.3389/fimmu.2022.915412. eCollection 2022.
8
An Interlaboratory Comparison on the Characterization of a Sub-micrometer Polydisperse Particle Dispersion.一种亚微米多分散颗粒分散体特性的实验室间比较。
J Pharm Sci. 2022 Mar;111(3):699-709. doi: 10.1016/j.xphs.2021.11.006. Epub 2021 Nov 20.
9
Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies.蛋白质治疗药物的聚集增强了它们的免疫原性:原因及缓解策略。
RSC Chem Biol. 2021 May 4;2(4):1004-1020. doi: 10.1039/d1cb00067e. eCollection 2021 Aug 5.
10
Development of vaccine formulations: past, present, and future.疫苗制剂的发展:过去、现在和未来。
Drug Deliv Transl Res. 2021 Apr;11(2):353-372. doi: 10.1007/s13346-021-00924-7. Epub 2021 Feb 17.